Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I dose-escalating and safety study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma.

Trial Profile

A Phase I dose-escalating and safety study of AZD8931 in combination with Oxaliplatin and Capecitabine chemotherapy in patients with Oesophago-gastric adenocarcinoma.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Nov 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sapitinib (Primary) ; Capecitabine; Oxaliplatin
  • Indications Adenocarcinoma; Carcinoma; Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms DEBIOC
  • Sponsors AstraZeneca
  • Most Recent Events

    • 31 May 2020 Results evaluating translational analysis impact of neoadjuvant Xelox with or without Sapitinib presented at the 56th Annual Meeting of the American Society of Clinical Oncology
    • 22 Nov 2019 Results assessing the recommended phase II dose (RP2D) of AZD8931 plus chemotherapy, and subsequently assess safety/preliminary clinical activity in patients with operable oesophagogastric cancer published in the European Journal of Cancer
    • 17 Aug 2018 Planned End Date changed from 29 Feb 2016 to 15 Nov 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top